文献速递湿疹皮炎与荨麻疹

抗菌治疗性衣物对中重度特应性皮炎无效:ABC随机对照试验

Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial).
PubMed 文献 · Br J Dermatol · 2024-01-01

ABC试验为实用性双盲多中心随机对照试验,纳入171例中重度特应性皮炎患者,按1:1:1分为标准治疗性衣物组、壳聚糖抗菌衣物组和银抗菌衣物组。结果显示52周内三组EASI无显著差异,患者报告结局、外用糖皮质激素用量及金黄色葡萄球菌定植亦无差异,提示抗菌治疗性衣物无额外获益。

要点

  • 抗菌治疗性衣物在52周内未改善中重度AD的EASI评分
  • 壳聚糖组与标准衣物组EASI差异为-0.1(95%CI -0.3~0.2;P=0.53)
  • 银组26周后表现略差,组×时间交互效应P=0.03,无严重不良事件

核心结论

  • 在中重度特应性皮炎患者中,抗菌治疗性衣物相比标准治疗性衣物未显示额外获益。

研究设计与样本

  • 实用性双盲多中心随机对照试验(NCT04297215),纳入各年龄段中重度AD患者171例,最终分析159例,按1:1:1随机分组。

主要发现

  • 52周内EASI在标准衣物组、壳聚糖组(-0.1,95%CI -0.3~0.2;P=0.53)和银组(-0.1,95%CI -0.3~0.2;P=0.58)间无差异。
  • 标准组与银组存在小幅显著组×时间交互效应(P=0.03),银组26周后表现更差。
  • 患者报告结局、外用糖皮质激素用量、金黄色葡萄球菌皮肤定植及医疗资源利用组间无差异,未观察到严重不良事件或银吸收。

关键数值与推荐

  • 主要结局为52周内EASI的组间差异;基线中位EASI在标准组、壳聚糖组、银组分别为11.8、11.3、11.6。
  • 依从性高:中位每周穿着7晚(四分位距3-7)。

临床怎么用

  • 中重度AD不应常规依赖抗菌治疗性衣物替代标准外用治疗,标准局部治疗仍为核心。

局限性

  • 未报告盲法实施细节及长期随访数据;银组26周后表现更差的具体机制未阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased Staphylococcus aureus (SA) colonization is considered an important factor in the pathogenesis of atopic dermatitis (AD). Antibacterial therapeutic clothing aims to reduce SA colonization and AD inflammation; however, its role in the management of AD remains poorly understood. OBJECTIVES: To investigate the effectiveness of antibacterial therapeutic clothing + standard topical treatment in patients with moderate-to-severe AD vs. standard therapeutic clothing + standard topical treatment; and, if effectiveness was demonstrated, to demonstrate its cost-effectiveness. METHODS: A pragmatic double-blinded multicentre randomized controlled trial (NCT04297215) was conducted in patients of all ages with moderate-to-severe AD. Patients were centrally randomized 1 : 1 : 1 to receive standard therapeutic clothing or antibacterial clothing based on chitosan or silver. The primary outcome was the between-group difference in Eczema Area and Severity Index (EASI) measured over 52 weeks. Secondary outcomes included patient-reported outcomes (PROs), topical corticosteroid (TCS) use, SA colonization, safety and cost-effectiveness. Outcomes were assessed by means of (generalized) linear mixed-model analyses. RESULTS: Between 16 March 2020 and 20 December 2021, 171 patients were enrolled. In total, 159 patients were included (54 in the standard therapeutic clothing group, 50 in the chitosan group and 55 in the silver group). Adherence was high [median 7 nights a week wear (interquartile range 3-7)]. Median EASI scores at baseline and at 4, 12, 26 and 52 weeks were 11.8, 4.3, 4.6, 4.2 and 3.6, respectively, in the standard therapeutic clothing group vs. 11.3, 5.0, 3.0, 3.0 and 4.4, respectively, in the chitosan group, and 11.6, 5.0, 5.4, 4.6 and 5.8, respectively, in the silver group. No differences in EASI over 52 weeks between the standard therapeutic clothing group, the chitosan group [-0.1, 95% confidence interval (CI) -0.3 to 0.2; P = 0.53] or the silver group (-0.1, 95% CI -0.3 to 0.2; P = 0.58) were found. However, a small significant group × time interaction effect between the standard and silver groups was found (P = 0.03), in which the silver group performed worse after 26 weeks. No differences between groups were found in PROs, TCS use, SA skin colonization and healthcare utilization. No severe adverse events or silver absorption were observed. CONCLUSIONS: The results of this study suggest no additional benefits of antibacterial agents in therapeutic clothing in patients with moderate-to-severe AD.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Ragamin A, Schappin R, de Graaf M, et al. Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial). Br J Dermatol. 2024. PMID: 37936331. doi:10.1093/bjd/ljad437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。